Replies to post #101482 on Biotech Values

[DewDiligence]

Here’s a snippet from Brugger’s presentation this morning:

“There’s been some speculation as to how the FDA’s action on generic Lovenox applies to generic Copaxone… What I like is the fact that FDA has shown it can work with applicants with high science and come up with a totality argument to tackle these complex-mixture drugs and make them generic. I think that very much plays into our favor for generic Copaxone.”